z-logo
open-access-imgOpen Access
EVALUATION OF CLINICAL OUTCOME OF ANTIPSYCHOTIC THERAPY IN SCHIZOPHRENIC PATIENTS IN PALU – INDONESIA
Author(s) -
Amelia Rumi,
Alwiyah Mukaddas,
Astriana,
Siti Radhiya
Publication year - 2022
Publication title -
indonesian journal of pharmacy
Language(s) - English
Resource type - Journals
eISSN - 2338-9486
pISSN - 2338-9427
DOI - 10.22146/ijp.1547
Subject(s) - risperidone , haloperidol , antipsychotic , positive and negative syndrome scale , schizophrenia (object oriented programming) , medicine , psychiatry , psychology , trifluoperazine , psychosis , calmodulin , dopamine , calcium
Schizophrenia is a severe mental disorder characterized by psychotic episodes. The first line of treatment for schizophrenia is the use of antipsychotics that is still subjective. There is still a need for research related to the use of antipsychotics to achieve effective treatment. This study aimed to compare the effectiveness of the First-Generation Antipsychotic (FGA) haloperidol, trifluoperazine and risperidone antipsychotic therapies as Second-Generation Antipsychotic (SGA) based on symptom reduction using the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) method in patients with acute schizophrenia and relapse hospitalization. This research used a quantitative analysis with a prospective approach where the sampling was conducted using total sampling and the data obtained were analyzed using independent t-test and linear regression analysis. There were 40 out of 120 patients who met the inclusion criteria, consisting of patients in groups of haloperidol, trifluoperazine and risperidone therapies with a therapeutic duration of 3–10 days. The results showed that the average PANSS-EC score of haloperidol medication of 15.35 was greater than that of trifluoperazine medication of 14.42 and the p-value showed no significant difference between the use of FGA, haloperidol and trifluoperazine with p = 0.190 (p> 0.05). The average PANSS-EC score of haloperidol medication (FGA) of 15.35 was greater than that of risperidone (SGA) of 13.6 and the p-value showed that there was a significant difference between haloperidol and risperidone with p = 0.027 (p< 0.05). The multivariate analysis showed p = 0.022 (p< 0.05) which means haloperidol showed the greatest symptom reduction among the three antipsychotic medications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here